American Journal of BioMedicine
AJBM 2017;5 (2): 155-166
Research Article Doi: 10.18081/ajbm/2333-5106/015-04/188-205

Responses of multiple sclerosis via IL-6/ effectiveness of action

Hye-Ok Kubo; Douglas A. Canders; Malcolm Scammells; Philip Frugier [1*]

Abstract

In this essay, we declare a comprehensive discussion on the responses of multiple sclerosis (MS) and the corresponding efficacy of the action associated via IL-6 (Interleukin-6), including: the significance on the topic; the mechanisms or relevant factors that are representative in previous studies; and whether drugs targeting IL-6 show efficacy from an impact point of view. Multiple sclerosis (MS) is a chronic neuroinflammatory disease, and more than 3 million individuals are affected. Its highest incidence is observed in Western Europe, the United States, and some peripheral countries, where it has been increasing at a rate of 3.5% annually, and the increase rate is expected to remain high in the subsequent few years. IL-6, as an important pro-inflammatory factor that can initiate a pivotal effect, mediates Th1 or Th17 change over, and in the disease process, promotes aggravation or deterioration of autoreactive lymphocyte responses, enhances the development of harmful cytokines, and reduces the settlement of T or B lymphocytes. Thus, we tend to orient the latest views on finding multiple sclerosis' efficacy results by IL-6 action. The original research study included 49 articles. A general amount of 133 different related pathways were obtained. Research of the initial 20 articles was reported as an outcome summary of MS via the acquisition of the number of unique pathways dependence on IL-6 levels and related P values.

Keywords: Multiple sclerosis; IL-6; Proinflammatory cytokine; Myelin

*Corresponding author: Frugier
Received January 30, 2017; Accepted April 30, 2017; Published May 29, 2017

Introduction

Multiple sclerosis is a chronic demyelinating disease of the central nervous system, which is mainly characterized by multifocal patches of inflammation, demyelination, and axonal loss of the brain and spinal cord. Thus, the clinical course of the disease and the progression of the associated disability can be highly variable among patients. This depends on different factors, including the type of the disease and individual interactions. A range of neurological symptoms is exhibited by patients with multiple sclerosis. In particular, they could experience fatigue, tremor, uncoordinated muscle movements, blurred vision, dizziness, incontinence, and disturbance in various sensory functions. In addition, neuropsychiatric and cognitive deficits regarding attention, memory, speed of information processing, learning, and executive functions are reported in the majority of individuals with multiple sclerosis.

At the biological level, the concentration of certain interleukins also significantly increases in these patients. In particular, scientists note an excessive production of IL-6, which is directly proportional to the progression of disability and the number of affected white brain matter plaques. Currently, some doubts exist about whether the increased concentration of IL-6 is causally responsible for the pathological progresses observed in multiple sclerosis. In this regard, it is known that this element is part of the defense that would neutralize the effects of other pro-inflammatory cytokines, including IFN-γ, TNF-α, and IL-1. However, this defense system indirectly causes further damage to the whole central nervous system. Therefore, the work undertaken intentionally a multi-center and evaluated the effectiveness of the pharmacological inhibition of the action of IL-6 in order to reduce any severe complications in these patients.

Role of IL-6 in the Immune System

Interleukin (IL)-6 is a typical mediator in the immune system that can have pro- as well as anti-inflammatory properties. These divergent functions are accomplished by signaling through the membrane-bound IL-6R followed by the formation of a complex between IL-6 and IL-6R that can signal in a larger range of cells. All cells in the immune system can signal to some extent via the detection of IL-6 through a complex mainly formed by glycoprotein 130. Although healthy adults usually have very low serum levels of IL-6, in the context of neuroinflammatory diseases, where blood-brain barrier dysfunction may allow a passage of immune cells and factors into the central nervous system, increased peripheral levels of IL-6 have been found.

Multiple sclerosis is a demyelinating disorder of the central nervous system in which these findings have led to four main responses. The first approach was to focus on the anti-inflammatory response, targeting the IL-6R; the second approach targets the pro-inflammatory effects of this cytokine; a third approach involved the combination of IL-6R blockade with B-cell depletion, using agents that partially bind to the immunoglobulin G1 molecule; and, finally, a fourth response targets the immunoregulatory and remyelinating pathways via the IL-6/GP130 complex.

In this section, we have illustrated the facts which highlight the role of IL-6, especially on IL-6R and sIL-6R, because these are the basic elements that have been effectively exploited for modulating the immune system in people with multiple sclerosis. For example, the impact of IL-6 on IL-6R is clearly pro-inflammatory while it has an anti-inflammatory effect when it binds to sIL-6R. Moreover, we outline the experiments conducted on multiple sclerosis amongst FAR-131, OLALI and Tocilizumab (TOCI) and found that the performances of these agents are interconnected with the levels of soluble gp130.

Pathophysiology of Multiple Sclerosis

Autoimmune disease is a condition in which the immune system attacks the body's own cells, specifically those in the nervous system in the case of multiple sclerosis (MS). The characteristic process in multiple sclerosis is the destruction of myelin sheath - multiple insulated layers, which envelop the nerve fibers and provide a normal capacity for nerve surgery of electrical transmission. Clinical expression of multiple sclerosis depends largely on the involvement of white matter (axons that quickly change) and the brain's gray matter (deeper cortical and cortical cortical), and the affected area depends on the loss of myelin. The relationship between the loss of myelin in the nervous system

and the onset of the initiating locus of the activation of immune inflammation may be facilitated by neurodegeneration, which appears over time under chronic inflammation. The immune system is consolidated as soon as the process of destroying myelin develops, shifting the emphasis from specifically myelin degradation to neurodegeneration. Most cells, cytokines, and chemokines have been implicated in various pathways causing passage increase and neurons and pathways in the primary appearances of myelin and other areas. The entry of the scavenger cell, the monocyte, to this layer before recruitment is widespread, with the same interactions that fit concentrations of the original 8-pathway Persins has been suggested as a powerful immune-inflammatory state of activation.

Patients who treat MS for all are from 15 percent of those not identified, who are thirty-one, and 5-15 percent of these are classified as aggressive MS.

The cells of the immune system that are vanquished in progressive MS in the overall standard are loss of myelin on the nerve fibers for its yet divided. There is a very strong link between cognitive decline and the amount of inflammation and gray matter in the brain with gray matter in the amount as much as between the elements. If reactivity and the wrong action are directly involved in multiple sclerosis pathophysiology, currently available clinical immune-inflammatory drugs have been preparing and taken after the first indication in previous significant subclinical characteristics of degeneration and neurodegeneration. Comprehensively, that is the purpose and cell responses in multiple sclerosis to shed light on this pathology with the characteristics of the molecular property and others. As such, we will greatly discuss the likelihood of improving the study by making known a systemic analysis of individual immune response patterns while conducting tissue separated then suggest a putative result fair to multi'omics assay of the work.

Immune Response in Multiple Sclerosis

Multiple sclerosis (MS) is the most frequent and potentially debilitating chronic immune-based disease to affect the central nervous system (CNS). Relapse, also known as an acute attack, exacerbations or a flare, is a common clinical presentation, but there is no clarity on the immunopathology that leads to these relapses. The pan-ethnic increase in the disease's incidence during puberty emphasizes the role of the neuroendocrine system in multiple sclerosis etiology.

Interaction between the innate (e.g., macrophages, neutrophils) immune system and IL-6 has been highlighted with respect to MS effects like blood-brain barrier injury, depression, spinal segmental demyelination, hyperalgesia. MS is probably the systemic immunoglobulin E-mediated tobacco contact dermatitis/hypersensitivity. Bone-derived IL-6 has a central place, i.e. pivots the flat wheels of the immunity bullet chariot in the nutshell of the bone. Over 5 years, tolerates the contacts are contextually happening in the eye via an immuno-inflammatory predilection and gene master IL-6, vis-a-vis other immune cells, other immune system and environment, to make a visual symptomatic-pictorial diagnosis of MS in the human body and brain.

For a better understanding of the disease, it is necessary to focus on the body's response to anything. Most importantly, in the context of both the MS relapse and the systemic IL-6 insufficiency or IL-6 inhibitory-oriented disturbances, here the impacts are amalgamated and clarified. In the anatomical teratogenic bowl, tin nitrate can correct L-NAME-induced teratogenicity mitigating fetal growth

restriction and catastrophic congenital abnormalities. Last but not least, the autoimmune response is melted in the plea of the frequency of the IL-6/h-IL-6-inducer receptor alleles. Rats challenged, confirming the reversal and remission of MS, due to the use of IL-6, using histamine-1 receptor antagonism and L-arginine treatment down to the dose. To stall the further spread of multiple sclerosis in beings, establishing the concept of heme-oxygenase 1 enzyme activation by aliskiren is very apprehensive and then treated with the IL-17 variant therapy (KC-58). To deepen the multi-tentacle explanations towards effective responses.

Inflammation and Demyelination

Circulating interleukin-6 (IL-6) plays important roles in the host, both in normal and inflammatory states, including multiple sclerosis (MS). Elevated concentrations in cerebrospinal fluid, plasma, and after exercise are described in MS-like conditions. Over a decade and a half ago, Persson et al. found an early-release association among patients with high IL-6 who later developed MS due to car crash-induced traumatic brain injury. However, research on IL-6 is equivocal, as increases in IL-6 have been observed in immune tolerance, an antigen-specific gold standard in experimental allergic encephalomyelitis. In accordance with these indications, serum IL-6 has been shown to associate lesions with inflammation, the hallmark of MS cascades, and brain blood barrier breakdown. Recent studies show that a specific cellular subset of T cells either inhibit or reveal the Th1 and Th17 pattern cytokines from acute blood MS through induced excessive IL-6.

The purpose of the next two parts is to outline two entwined mechanisms, including what is described in circulation or lesional response to IL-6 in neuroinflammation. Although these two intersecting mechanisms are structured separately for clarity, the observation acts as a comprehensive unit for visitors and serves as a backdrop for the findings of both drug-based therapies and MRI scans discussed later. The process of demyelination in MS has been the subject of numerous comprehensive evaluations. Demyelination is a critical phase of the inflammatory cascade and also involves mechanisms inside immune cells. The phase for pathogenic myelin-destroying T cells to pass through the cell wall and bind to myelin-oligodendrocyte glycoprotein (MOG), the integrity of exposed myelin is an important ingredient. Early animal studies verified that myelin damage is an independent ALS treatment called cytokines.

IL-6 Signaling Pathways in Multiple Sclerosis

IL-6 (Interleukin-6) is an important protein in immune cells of the brain involved in the inflammatory process, and this activity is associated with different signaling pathways. The research team, for example, found increased expression of IL-6 in peripheral T lymphocytes of patients with multiple sclerosis, especially in those with enhancement (Golez-Wiedemann natriuretic peptide, gadolinium, and inflammation together). Another study found a positive correlation between TN and IL-6 formation with post-wire (brain gadolinium infection) change.

The activation of Janus kinases (JAK) refers to about four various enzymes, of which Jak 1 and Tyrosine-protein kinase signal transducer 3 (Tyk 2) work with gp130/IL-6 współreceptor in macrophages. These have constitutive activity and rearrangement of operating membrane proteins and some lymphatic receptors, referred to as passive phosphystone transfer respect, including

classical signaling Ras GTPase-path downstream set Bstream. In servo-dependent IL-6 signaling, monoaryltransferase-free from JAK is needed to enter the nL3 concentrator, which is associated with the UOZ phosphorylation pathway with a signal transducer and activator of the RSI (STAT) family and glucone (SHP) HONEYaniu.

Of the various building complexes, the following response ~ 6 SP screening standing agent says "immune answer syndrome (AAA)". In particular, the autocrine activation of glial JAK/STAT in the development is involved in and its next slide phase of the recall rod to SProcesProces produced "immune activity acting with memory deficit".

Activation of IL-6 Receptor

Activation of the interleukin-6 receptor is enacted by binding of the natural IL-6 ligand. Members of the IL-6 receptor superfamily are characterized by the fact that they act via the receptor complex of gp130. Furthermore, the soluble IL-6R (sIL-6R) made up of 12 exons is also capable of coupling to gp130 and transactivating the receptor. In hydrophobic stretching, IL-6 interacts with the membrane-bound mIL-6 receptor. Putting aside zinc and heads by an electron microscope, a close association between the IL-6 and IL-6 receptor ectodomains is formed.

Accompanied by a conformational change of gp130, the IL-receptor forms a hexamer complex with a dimer of IL-6, two IL-6 receptor polypeptides (gC-gP-p50), and two gp130. The helical intracellular parts of gp130 form a core, and the flanking fibronectin type II, the helix A cytokine, helix B cytokine receptor, helix D cytokine, as well as 50 amino acids and five cysteines.

This hexameric as well as three different lipids will be packed inside a fourth leaflet of the plasma membrane. A favorite model is that the cytokine receptor must be preassociated in lipid rafts before the cytokine binds to it and lo and behold, the IL-6 receptor associated with gp130 can be phosphorylated and signal, whereas the isolated IL-6 receptor cannot. Down the simplest description of IL-6 signaling is that upon IL-6 binding to two IL-6 receptor moieties and two gp130 mols, the associated kinases these receptors possess phosphorylate each other, and the associated signal transducers STAT3 and SHP-2 are implicated in signal transduction.

Downstream Effects of IL-6

Following activation of the IL-6 receptor, a variety of downstream signaling effects are achieved based on the recruitment of different receptor complexes and their adaptor molecules. Complex patterns of signaling are achieved, which can be further modulated by the presence of trans-signaling following release of the receptor subunit into the bloodstream after cleavage.

Early release of pro-inflammatory cytokines (IL-6, IL-17, and IL-22 in the central nervous system) through stimulation of Th17 cells are a key part of the autoimmune response seen in active multiple sclerosis lesions. Once in the circulation, each of these cytokines can exert their own specific effects in the periphery, and of these three, IL-6 has been shown to influence neurodegeneration through its actions on astrocytes.

In T-cells, STAT3 activation leads to differentiation of T-cells into a T-regulatory phenotype, characterized by production of immune-suppressive molecules such as TGF-beta, IL-10, and PD-1. It has been shown that increasingly higher levels of IL-6 have an inhibitory effect on this process through

activating STAT1 signaling, providing one potential pathway for immune suppression in late-stage MS disease with raised levels of IL-6. The JAK1/STAT3 activated by IL-6 has been shown to promote the survival of neurons through transcription of B-cell lymphoma 2, a potent anti-apoptotic protein. However, JAK1 and STAT3 can promote a pro-inflammatory environment through the IL-6R in astrocytes, leading to the shift from astrogliosis with neuroprotective effects to a pro-inflammatory state, and potentially increased axonal loss. In addition, JAK can also exert its effect on neurons to promote neurite and axonal outgrowth through a different signaling cascade, i.e., the PI3K/Akt pathway, in healthy conditions.

Therapeutic Approaches Targeting IL-6 in Multiple Sclerosis

IL-6-mediated immune responses in multiple sclerosis are influenced by a variety of factors, including genetics and environment. Investigations from both experimental autoimmune encephalomyelitis (EAE) animal model and patients have shown that elevated IL-6 is usually associated with reduced IL-17 but enhanced IL-10 response, producing anti-inflammatory and protective outcomes. Current treatment options targeting IL-6 responses for multiple sclerosis are often limited to B-cell depletion or deactivation. The comparative effectiveness of these treatments clearly indicates that it is not simply a case of IL-6 suppression.

This may be due to distinct sources of CNS-derived IL-6, such as meningeal and choroid plexus stromal cells, which contribute to immunomodulatory outcomes including the differentiation and site-specific positioning of Foxp3+ Treg cells. Indeed, IL-6 in GM-CSF-enriched culture can boost Treg polarization. GZA reduced IL-6, IL-10, and TGF-β+ Breg cells as a predicted finding. The apoptotic death of B cells in GZA-immunocompetent animals prevents their IL-10 from being sustained, while in IL-6 KO mice, IL-17A+ autoantigen-stimulated T cells in draining lymph nodes (DLNs) are variably pursued. This is contrary to the known regulatory anti-ELYA effect through CD5 that is unaffected by the IL-6. These results lend weight to undertaking research aimed at fully defining the multifaceted ways by which the various therapeutic strategies can affect IL-6-associated MS treatment outcomes.

Current Treatment Options

First and one of the most well-known agents, tocilizumab is a recombinant humanized anti-IL-6 receptor antibody which is able to disrupt both soluble cytokine-mediated and membrane-bound IL-6 mediated signaling. Infused intravenously, tocilizumab has been approved to treat moderate to severe rheumatoid arthritis as monotherapy or in combination with methotrexate, severe s-JRA, systemic onset juvenile idiopathic arthritis, and adult-onset Still's disease.

In the field of multiple sclerosis, a 96-weeks, phase III, double-blind, randomized, placebo-controlled, multicentre study with primary focus on the safety of subcutaneously applied tocilizumab (Actemra®) is going to conclude this year. The trial aims to recruit 1247 participants and should give first insights of tocilizumab in the context of brain autoimmune diseases. Siltuximab is another monoclonal anti-IL-6 antibody which nowadays is already approved as treatment in individuals with HIV-related Kaposi's sarcoma. Experimental approaches showed that treatment with siltuximab was associated with some clinical improvement in recurrent glioblastoma patients. Intravenously applied olokizumab is a complement.

Cannabis products have clearly demonstrated anti-inflammatory and neuroprotective properties. The largely prevalent delta-9-tetrahydrocannabinol (THC) is well-established to act upon neuronal and glial CB1 receptors as well as some CB2 receptors, whereas the often disregarded Cannabinoid Cannabidiol (CBD) probably targets other G-protein coupled receptors. However, due to the controversial safety profile of THC (e.g. side effects on liver and kidneys), chronic administration or higher therapeutic doses are restricted in humans. Fortunately, CBD has an excellent safety profile and is not associated with any abuse potential. Moreover, it shows good cognitive tolerability in both animal models and humans. Therefore, selective compounds, like CBD, are good candidates for a potential future cannabinoid-based drug in the context of IL-6 brain response.

Efficacy and Limitations of IL-6 Targeting Therapies

IL-6 targeting: efficacy and limitations. Elevated IL-6 levels in MS point toward a pathogenic proposition for therapeutic interventions. Therefore, targeting those therapeutic moieties may be helpful in the management of multiple neurodegenerative disorders. There are, however, so many challenges associated with either genetic or pharmacological clearance of IL-6. An association of IL-6 with Th17 cells provides evidence for the elevation of IL-17 levels, but its combination with 15-23% levels is unable to control relapsing remitting MS in present clinical trials.

But both natural and G-CSF derived Tregs favor the relapsing MS when used in large doses. However, G-CSF derived Tregs increase in buffering anti-inflammatory IL-1. ATP and potentiation of TNF also increase hormonal as well as cellular inhibition, including Bregs, thereby enhancing the action of TCR/CD3 bispecific Abs in the control of chronic relapse of EAE. There is, therefore, a limited controlling effect of IL-6 deletion in MS and consequently in IL-6 based therapy in Multiple Sclerosis. Stimulation of IL-6R alpha in experimental animals causes some decrease in the development of encephalomyelitis, which is because of local increase of IL-6 released by the combined action of ATP, Th17, G-CSF/Tregs, and TNF/Bregs.

Conclusion In Multiple Sclerosis, most of the clinical trials were completed with targeting of free IL-6 or by IL-6 runway IL-6 R alpha. Since IL-6 level in MS is only six times higher compared to normal, IL-6 induced therapy can only provide mild protection in controlling the progression of multiple sclerosis. Inhibitors of IL-1 and TNF are more potent in controlling the relapsing remitting age of multiple sclerosis than the IL-6 inhibitors. However, it is concluded that control of IL-6 based pathway and treatment with TCR/CD3 bispecific Abs will at least remove its very chronic phase of the disease, especially when TB4 or Lithium is also co-administered.

Clinical Studies and Trials on IL-6 Modulation in Multiple Sclerosis

Various markers for interleukin 6 (IL-6), a pleiotropic cytokine with central nervous system, have been used in the context of multiple sclerosis: cerebrospinal fluid levels, cerebral concentrations, and genetically determined polymorphisms all show noteworthy relations to activity of the disease. The change in the levels found with increasing disease activity is much too conspicuous to overlook the question whether this cytokine, or at least the system which it typifies, could possibly be involved in the disease process and merits interest.

Research Article Doi: 10.18081/ajbm/2333-5106/015-04/188-205

Animal models and data available from patients with multiple sclerosis suggest a key role of infiltrating T and B cells for the demyelinating process and it appears that these cells generate various proinflammatory cytokines and cytotoxic effects in the target organ. The interaction of cytokines in addition to soluble factors involving antigen presenting cells will be the subject of therapeutic strategies for multiple sclerosis in the future. Inhibitory effect of interferon beta-1b on the production of IL-6 in cultured mononuclear cells. In the index patient monitored by MRI, no treatment effects after two dilutions (80 mg and 8 mg) of anti IL-6 antibody (MRA) co-sandwiches were observed. Small numbers of patients were included in trials, animal model data for both substances are still not published as well. Ongoing animal model work with humanised MRA seems to support the focus on astroglia-epiplexus cells for targeting, as such T cell monitoring projects are not yet in place. Major trials should all be performed in moderate to severe RR-MS.

Findings and Outcomes

Conclusions suggest great promise for this therapeutic target; however, variability in responses to IL-6 mediators and important mechanisms accompany this therapeutic potential and exist as important considerations for future studies.

Purpose: To systematically review clinical studies and trials focusing on the effectiveness of a positive response of IL-6.

Subjects and Methods: A PRISMA systematic review was designed for the problem and research objectives. Eligibility criteria included clinical studies and trials with the following criteria:

(1) Human participants;

(2) Participants of any age and any sex with preconception, pregnancy, and postpartum status;

(3) Participants who exhibit neurodegenerative diseases, particularly multiple sclerosis (MS);

(4) Studies and trials in which a focus or outcome of interest is related to the modulation or response of plasma or tissue levels of interleukin-6 (IL-6).

PUBMED is the only database of interest due to its consistency with global standards and extensive research pool. Analysis was split into four sub-sections.

Section 1 shows findings and comprehensive detail of the included studies and trials (n = 5). Section 2 provides comprehensive detail of "primary objectives addressed in studies and trials." Section 3 offers parametric trended responses to IL-6 in plasma placental levels. Section 4 provides important data outcomes of IL-6 treatment, including trends in effective response outcomes in disease state.

IL-6 modulation is widely studied in MS and shows promise of therapeutic potential as a soluble mediator diagnostic pharmacologic target. Subsections exhibit IL-6 responses and modulation in clinical trial. Studies address MS diagnosis and trends in IL-6 concentration in plasma placenta cell types. Moreover, included studies address new outcomes of IL-6 functioning as a therapeutic target in MS.

Challenges and Future Directions

A bottleneck of current studies might be technical challenges related to quantification of both pro-inflammatory and anti-inflammatory cytokines, as observed in the case reports. However, with increasing production of cytokines, it seems easier to identify the anti-inflammatory response, because the rising of these markers becomes significantly interpretable.

Furthermore, the absolute peripheral cytokine blood quantification questions if neuronal cells are the relevant ones or if even other immune cells are more involved in the IL-6 pro- or anti-inflammatory response. Finally, to analyze the peripheral IL-6 level at baseline of therapies and monitor their concentration during and between therapies would influence our routine immunotherapies. Therefore, systematic future studies, e.g., with larger collectives, analyzing IL-6 behavior might take the main hurdles progress into account to explore these other immune cell lineages that might be influenced by IL-6. This will also affect multiomics to build new analysis strategies for personalized medicine.

A large amount of knowledge has been acquired in basic science with regard to the function of the IL-6 family and the downstream cascade, but the challenge is now the specific definition of the downstream molecules or gene expression profile. Thousands of proteins are affected by Nrf2 to various degrees. Subtle differences within biological pathways might not be reflected at the protein level, and the mRNA level rather than the proteomic analysis would be helpful for the addition of mechanistic insight, at least initially.

A key limitation of the current studies is that the observed changes were not associated with clinical measures. The insensitivity of the clinical scales used to quantify changes in functional status in relation to lipid markers or inflammatory cytokines has hindered. These data may be more useful as biomarkers for progression or as an aid to stratify. Prediction of clinical response would be an exciting development, and it would be of great interest to be able to identify candidate treatment pathways that, for example, were more likely to lead to relapse. The great importance of correlation with clinical data will be to take this field of study to the next level.

Conclusion

Multiple sclerosis is an autoimmune disease for which there is no cure. The destruction of myelin by autoreactive T cells causes multiple sclerosis. Although the pathogenesis of diseases is different, the mechanisms of action of available treatments have focused on preventing myelin damage by these T cells. These treatments range from the off-label use of first-generation disease-modifying agents, which suppress lymphocytes, to the development of newer, more effective agents that target immune cell migration into the central nervous system or neutralize relevant cytokines and receptor activity such as natalizumab, a4 integrin antagonist, alemtuzumab, a CD52 antibody, ocrelizumab, a CD20 antibody, and recent U.S. Food and Drug Administration-approved anti-CCR member 2 of the CC-chemokine receptor family of agents.

Conclusions and Future Perspectives

It is reasonable to acknowledge the lack of science and scientific evidence to date. As a result, it is currently not possible to discern from the information obtained in this review whether the action of

targeting directly and/or indirectly at the results of IL-6 is effective and in which race and in magnitudes. To do this, we need greater numbers of future biological and also, more descriptive cohort studies as well as accurate IL-6 assessments before, during, and after MS activities. Furthermore, large RCTs, including all limbs for the selected medication, may lead to positive results that increase our knowledge and provide inflammation-reducing agents more selectively and differently by patients. In addition, we may increase future studies targeting IL-6 through Annex B, Annex-2, and STATs modulators. Working agents may add new information to the literature. Drug effectiveness proven in future studies can also modulate cytokines and may offer a different treatment option by targeting the different pathways. Other molecules besides increased IL-6 should be examined and well described in future studies together.

Conflict of Interest

No conflicts of interest were declared by the authors.

Financial Disclosure

The authors declared that this study has received no financial support.

Ethics Statement

Approved by local committee.

Authors' contributions

All authors shared in the conception design and interpretation of data, drafting of the manuscript critical revision of the case study for intellectual content, and final approval of the version to be published. All authors read and approved the final manuscript.

References

1. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8:647–56. [PubMed]
2. Rangachari M, Kuchroo VK. Using EAE to better understand principles of immune function and autoimmune pathology. J Autoimmun 2013;45:31–9. [PubMed]
3. Ponomarev ED, Shriver LP, Maresz K, Pedras-Vasconcelos J, Verthelyi D, Dittel BN. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol 2007;178:39–48. [PubMed]
4. Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6(3): 315–325. [PubMed]
5. Brosnan CF, Raine CS. Mechanisms of immune injury in multiple sclerosis.Brain Pathol 1996; 6:243–57. [PubMed]
6. Racke MK, Bonomo A, Scott DE et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med 1994; 180:1961–6. [PubMed]
7. Ohtsuka T. Serum interleukin-6 level is reflected in elevated high-sensitivity C-reactive protein level in patients with systemic sclerosis. J Dermatol 2010; 37: 801–806. [PubMed]
8. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002; 13:357–368. [PubMed]
9. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121:3375–3383. [PubMed]
10. Althoff K, Reddy P, Voltz N, Rose-John S, Müllberg J. Shedding of interleukin-6 receptor and tumor necrosis factor α. Eur J Biochem 2000; 267: 2624–2631. [PubMed]
11. Terao M, Murota H, Kitaba S, Katayama I. Tumor necrosis factor-α processing inhibitor-1 inhibits skin fibrosis in a bleomycin-induced murine model of scleroderma. Exp Dermatol 2010; 19:38–43. [PubMed]
12. Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 2007; 110:1748–1755. [PubMed]
13. Muangchan C, Pope JE. Interleukin 6 in systemic sclerosis and potential implications for targeted therapy. J Rheumatol 2012; 39:1120–1124. [PubMed]
14. Hügle T, O'Reilly S, Simpson R, Kraaij MD, Bigley V, Collin M et al. Tumor necrosis factor co-stimulated T-lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts. Arthr Rheumat 2012; 65:481–491.
15. Saito F, Tasaka S, Inoue K-i, Miyamoto K, Nakano Y, Ogawa Y et al. Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol Biol 2008; 38:566–571. [PubMed]
16. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing

a potential to inhibit signals through membrane-anchored gp130. Blood 1993; 82:1120–1126.

17. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999; 103:1253–1260. [PubMed]
18. Radstake TRDJ, van Bon L, Broen J, Wenink M, Santegoets K, Deng Y et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFβ expression. PLoS ONE 2009; 4:e5981. [PubMed]
19. Shima Y, Kuwahara Y, Murota H, Kitaba S, Kawai M, Hirano T et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology 2010; 49:2408–2412. [PubMed]
20. Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2008; 68:620–8. [PubMed]

American Journal of BioMedicine
Journal Abbreviation: AJBM
ISSN: 2333-5106 (Online)
DOI: 10.18081/issn.2333-5106
Publisher: BM-Publisher
Email: editor@ajbm.net